

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bimacure 500mg Intrauterine Suspension for Cattle

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each syringe contains:

Active substance:

Cefapirin 500 mg
(as Cefapirin benzathine)

Excipients:

Qualitative composition of excipients and other constituents
Macrogol cetostearyl ether-20
Macrogol cetostearyl ether-12
Hydrogenated castor oil
Triglycerides, medium chain

A creamy, oily suspension.

3. CLINICAL INFORMATION

3.1 Target species

Cows.

3.2 Indications for use for each target species

For the treatment of subacute and chronic endometritis in cows (at least 14 days after parturition) caused by bacteria susceptible to cefapirin.

3.3 Contraindications

Do not use in animals with known hypersensitivity to cephalosporins or to any of the excipients.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Use of the veterinary medicinal product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefapirin and may decrease the effectiveness of the treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Penicillin and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillin may lead to cross reactions to cephalosporins and *vice versa*.

Allergic reactions to these substances are occasionally serious.

1. Do not handle this veterinary medicinal product if you know you are sensitised or if you have been advised not to work with such preparations.
2. Handle this veterinary medicinal product with great care to avoid exposure, taking all recommended precautions.
3. If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.

Personal protective equipment consisting of protective gloves should be worn when handling the veterinary medicinal product.

Accidental spillage on the skin should be washed off immediately with soap and water.

Wash hands after use.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cattle (cows):

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Allergic reaction
--	-------------------

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product.

Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

The use is not recommended during pregnancy.
Can be used during lactation.

3.8 Interaction with other medicinal products and other forms of interaction

Not to be administered concurrently with other intrauterine antibiotic preparations.

3.9 Administration routes and dosage

For intrauterine use.

The contents of one syringe of the veterinary medicinal product, corresponding to 500 mg of cefapirin (as cefapirin benzathine) should be introduced into the lumen of the uterus using the disposable catheter provided as follows:

1. The product may settle but can be re-suspended by gentle shaking into a homogeneous suspension.
2. Fix the syringe to the catheter.
3. Take the cervix of the uterus into one gloved hand introduced into the rectum.
4. Introduce the catheter through the cervix into the lumen of the uterus, by gentle oscillating movements of the cervix.
5. Inject the contents of the syringe into the uterus.

Depending on the response, a second treatment 7-14 days later may be required in some cases if clinical signs persist.

In animals that have been inseminated, the veterinary medicinal product may be used one day after insemination. In cases of pyometra, pre-treatment with prostaglandin is recommended in order to induce luteolysis and remove debris from the uterine cavity.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

The veterinary medicinal product is supplied as a single dose syringe therefore overdose is unlikely to occur.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Meat and offal: 1 day.
Milk: Zero hours.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QG51AA05.

4.2 Pharmacodynamics

Cefapirin, a first-generation cephalosporin, is a broad-spectrum antibiotic with bactericidal action against gram-positive and gram-negative bacteria. Cefapirin is resistant to the action of penicillinase.

4.3 Pharmacokinetics

After intrauterine treatment systemic absorption is low, which is reflected by the low plasma levels of cefapirin observed shortly after treatment. High cefapirin concentrations are observed in endometrium.

Twelve hours after treatment, cefapirin levels in plasma are below detectable levels. Cefapirin concentrations in endometrium can be observed up to 24 hours.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions
Syringes are for single use only.

5.4 Nature and composition of immediate packaging

Low linear density polyethylene syringe barrel with low density polyethylene plunger and cap containing 19g of oily suspension, packed in boxes of 10 syringes.
Intrauterine catheters are provided for administration.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Bimeda Animal Health Limited

7. MARKETING AUTHORISATION NUMBER

Vm 50146/4045

8. DATE OF FIRST AUTHORISATION

15 June 2022

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

May 2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Gavin Hall
Approved: 19 May 2026